Galapagos NV Announces Gamgertamig Preliminary Phase 1b Data and Poster Presentation at 2026 ASH Meeting
Galapagos NV announced the acceptance of a poster presentation at the 2026 American Society of Hematology Annual Meeting, scheduled for December 12-15, featuring preliminary data for gamgertamig in relapsed/refractory autoimmune cytopenias. Gamgertamig is an investigational BCMAx
